- Home
- GLXG vs PROK Comparison
GLXG vs PROK Comparison
Compare GLXG & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLXG
- PROK
- Stock Information
- Founded
- GLXG 2013
- PROK 2015
- Country
- GLXG Hong Kong
- PROK United States
- Employees
- GLXG N/A
- PROK N/A
- Industry
- GLXG
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GLXG
- PROK Health Care
- Exchange
- GLXG NYSE
- PROK Nasdaq
- Market Cap
- GLXG 70.4M
- PROK 220.6M
- IPO Year
- GLXG 2024
- PROK N/A
- Fundamental
- Price
- GLXG $1.81
- PROK $1.74
- Analyst Decision
- GLXG
- PROK Buy
- Analyst Count
- GLXG 0
- PROK 5
- Target Price
- GLXG N/A
- PROK $4.50
- AVG Volume (30 Days)
- GLXG 856.6K
- PROK 431.7K
- Earning Date
- GLXG 12-03-2024
- PROK 11-12-2024
- Dividend Yield
- GLXG N/A
- PROK N/A
- EPS Growth
- GLXG N/A
- PROK N/A
- EPS
- GLXG 0.04
- PROK N/A
- Revenue
- GLXG $3,858,088.00
- PROK N/A
- Revenue This Year
- GLXG N/A
- PROK N/A
- Revenue Next Year
- GLXG N/A
- PROK N/A
- P/E Ratio
- GLXG $88.73
- PROK N/A
- Revenue Growth
- GLXG N/A
- PROK N/A
- 52 Week Low
- GLXG $1.51
- PROK $1.18
- 52 Week High
- GLXG $16.93
- PROK $4.44
- Technical
- Relative Strength Index (RSI)
- GLXG N/A
- PROK 46.63
- Support Level
- GLXG N/A
- PROK $1.50
- Resistance Level
- GLXG N/A
- PROK $1.81
- Average True Range (ATR)
- GLXG 0.00
- PROK 0.20
- MACD
- GLXG 0.00
- PROK -0.01
- Stochastic Oscillator
- GLXG 0.00
- PROK 32.26
About GLXG GALAXY PAYROLL GROUP LTD
Galaxy Payroll Group Ltd provides payroll outsourcing, employment, consultancy, and market research services based in Hong Kong. Its client base includes retail, trading, industrial, IT, financial, and professional services industries. Geographically, the company derives maximum revenue from its clients in the People's Republic of China and the rest from Hong Kong, Macau, Taiwan, Japan, Thailand, Singapore, and other countries.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease.